High response incidence seen for axatilimab in recurrent, refractory graft-versus-host disease

Published Date: 25 Sep 2024

For patients with recurrent or refractory graft-versus-host disease (GVHD), the colony-stimulating factor 1 receptor (CSF1R)-blocking antibody axatilimab results in a high incidence of overall response, according to a study ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.

2.

GuCS: Genitourinary Cancers Symposium

3.

Obesity-associated cancers tripled nationwide over past two decades

4.

A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma

5.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot